Pharmacokinetics of obinutuzumab in Chinese patients with B-cell lymphomas-Reference-Cited by-同舟云学术

Pharmacokinetics of obinutuzumab in Chinese patients with B-cell lymphomas

Published:2017-02-14 Issue:7 Volume:83 Page:1446-1456
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Zhai John¹,Qin Yan²,Zhu Jun³,Song Yuqin³,Shen Zhixiang⁴,Du Xin⁵,Jamois Candice⁶,Brewster Michael⁷,Shi Yuankai²,Shi Jun¹

Affiliation:

1. Roche Innovation Center Shanghai; Shanghai China

2. Department of Medical Oncology; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC); Beijing China

3. Department of Lymphoma, Beijing Cancer Hospital; Peking University; Beijing China

4. Department of Hematology, Ruijin Homainlyspital; Shanghai Jiaotong University; Shanghai China

5. Department of Hematology; Guangdong General Hospital/Guandong Academy of Medical Sciences; Guangzhou Guangdong China

6. Roche Innovation Center Basel; Basel Switzerland

7. Roche Innovation Center Welwyn; Welwyn Garden City UK

Funder

F. Hoffmann-La Roche

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.13232/fullpdf

Reference26 articles.

1. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands;Southan;Nucl Acids Res,2016

2. The Concise Guide to PHARMACOLOGY 2015/16: Overview;Alexander;Br J Pharmacol,2015

3. Li XQ Li GD Gao ZF Zhou XG Zhu XZ The relative frequencies of lymphoma subtypes in China: a nationwide study of 10002 cases by the Chinese Lymphoma Study 2011

4. Preservation of lower incidence of chronic lymphocytic leukemia in Chinese residents in British Columbia: a 26-year survey from 1983 to 2008;Mak;Leuk Lymphoma,2014

5. Obinutuzumab: a new class of anti-CD20 monoclonal antibody;Gagez;Curr Opin Oncol,2014

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Monoclonal Antibodies, Bispecific Antibodies and Antibody-Drug Conjugates in Oncohematology;Recent Patents on Anti-Cancer Drug Discovery;2020-12-29

2. Safety, tolerability and pharmacokinetics of shorter duration of infusion of obinutuzumab in Japanese patients with B-cell non-Hodgkin lymphoma: final results of the phase II GATS study;Japanese Journal of Clinical Oncology;2018-06-22

3. Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial;Cancer Communications;2018-05-30

4. Discovery and Development of Obinutuzumab (GAZYVA, GAZYVARO), a Glycoengineered Type II Anti-CD20 Antibody for the Treatment of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia;Successful Drug Discovery;2018-04-16

5. Challenges and Opportunities With Oncology Drug Development in China;Clinical Pharmacology & Therapeutics;2018-03-08